Anticoagulant agents useful in treatment of thrombosis

Abstract

Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

1 . A method for inhibiting thrombosis in an animal comprising administering an effective dose of an anti-coagulation factor IX/IXa monoclonal antibody having self-limiting neutralizing activity.  
     
     
         2 . The method of  claim 1  further comprising administering acetylsalicylic acid in combination with the anti-coagulation factor IX/IXa monoclonal antibody.  
     
     
         3 - 5 . (canceled)  
     
     
         6 . The method of  claim 1  or  2  wherein the anti-coagulation factor IX/IXa monoclonal antibody has the identifying characteristics of SB 249413, SB 249415, SB 249416, SB 2249417, SB 257731 or SB 257732.  
     
     
         7 . The method of  claim 1  or  2  wherein the anti-coagulation factor IX/IXa monoclonal antibody has the identifying characteristics of SB 249417.  
     
     
         8 - 9 . (canceled)  
     
     
         10 . The method of  claim 1  or  2  wherein the thrombosis is associated with myocardial infarction, unstable angina, atrial fibrillation, stroke, renal damage, pulmonary embolism, deep vein thrombosis, percutaneous translumenal coronary angioplasty, disseminated intravascular coagulation, sepsis, artificial organs, shunts or prostheses.  
     
     
         11 - 38 . (canceled)  
     
     
         39 . The method of  claim 10  wherein the thrombosis is associated with stroke.  
     
     
         40 . The method of  claim 10  wherein the thrombosis is associated with sepsis.  
     
     
         41 . The method of  claim 1  wherein the anti-coagulation Factor IX/IXa monoclonal antibody binds with an epitope of the Factor IXgla domain.  
     
     
         42 . The method of  claim 41  wherein the epitope is located within residues 3-11 of the Factor IXgla domain.  
     
     
         43 . The method of  claim 42  wherein the antibody has a binding affinity of at least 4 nM.